HUP0303881A3 - Pharmaceutical compositions containing fatty alcohols and fatty acid esters useful for treatment of inflammation - Google Patents

Pharmaceutical compositions containing fatty alcohols and fatty acid esters useful for treatment of inflammation

Info

Publication number
HUP0303881A3
HUP0303881A3 HU0303881A HUP0303881A HUP0303881A3 HU P0303881 A3 HUP0303881 A3 HU P0303881A3 HU 0303881 A HU0303881 A HU 0303881A HU P0303881 A HUP0303881 A HU P0303881A HU P0303881 A3 HUP0303881 A3 HU P0303881A3
Authority
HU
Hungary
Prior art keywords
inflammation
treatment
pharmaceutical compositions
acid esters
compositions containing
Prior art date
Application number
HU0303881A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of HUP0303881A2 publication Critical patent/HUP0303881A2/hu
Publication of HUP0303881A3 publication Critical patent/HUP0303881A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU0303881A 2001-04-11 2002-04-11 Pharmaceutical compositions containing fatty alcohols and fatty acid esters useful for treatment of inflammation HUP0303881A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14253501A IL142535A0 (en) 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of inflammation
PCT/IL2002/000294 WO2002083122A1 (en) 2001-04-11 2002-04-11 Fatty alcohols and fatty acid esters useful for treatment of inflammation

Publications (2)

Publication Number Publication Date
HUP0303881A2 HUP0303881A2 (hu) 2004-03-01
HUP0303881A3 true HUP0303881A3 (en) 2009-10-28

Family

ID=11075312

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303881A HUP0303881A3 (en) 2001-04-11 2002-04-11 Pharmaceutical compositions containing fatty alcohols and fatty acid esters useful for treatment of inflammation

Country Status (17)

Country Link
US (1) US20060183797A1 (hu)
EP (1) EP1385500B1 (hu)
JP (1) JP2004525180A (hu)
KR (1) KR20030096312A (hu)
CN (1) CN100352433C (hu)
AT (1) ATE475416T1 (hu)
AU (1) AU2002255241B2 (hu)
CA (1) CA2442953A1 (hu)
DE (1) DE60237148D1 (hu)
HU (1) HUP0303881A3 (hu)
IL (1) IL142535A0 (hu)
MX (1) MXPA03009341A (hu)
NO (1) NO20034558L (hu)
NZ (1) NZ528784A (hu)
PL (1) PL366586A1 (hu)
WO (1) WO2002083122A1 (hu)
ZA (1) ZA200307783B (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
EP1900364B1 (en) 2001-04-18 2013-09-25 ProMetic BioSciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
PT1509618E (pt) 2002-05-13 2008-12-02 Arexis Ab Condições autoimunes e deficiências de nadph-oxidase
BR0314554A (pt) * 2002-10-10 2005-08-09 Yeda Res & Dev ésteres básicos de álcoois graxos e sua aplicação como agentes anti-inflamatórios ou imunomoduladores
KR101120775B1 (ko) 2003-02-07 2012-04-18 프로메틱 바이오사이언시즈 인코포레이티드 적혈구생성의 자극제로서의 중쇄 지방산, 글리세리드 및유사체
US7612111B2 (en) * 2003-03-20 2009-11-03 Imagenetix, Inc. Esterified fatty acid composition
US20050158329A1 (en) 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
KR100767701B1 (ko) * 2004-04-24 2007-10-18 김상희 모노아세틸디아실글리세롤류 화합물을 유효성분으로 함유하는 면역조절제 및 항암제
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
JP2008540394A (ja) 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
JP5046926B2 (ja) * 2005-05-16 2012-10-10 日本水産株式会社 炎症性疾患予防又は治療剤
US7294739B1 (en) 2006-11-06 2007-11-13 Teva Pharmacaetical Industries Ltd. Basic amine esters or oleic acid and their use as anti-inflammatory or immunobodulatory agents
KR100787765B1 (ko) * 2006-11-07 2007-12-24 고려대학교 산학협력단 팔미트산을 포함하는 알츠하이머병의 예방 또는 치료용조성물
US20100047327A1 (en) * 2007-01-31 2010-02-25 Tetsuji Kuwahara Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same
EP2117301A4 (en) * 2007-02-26 2010-04-14 Yeda Res & Dev USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS
US7964751B2 (en) 2007-02-26 2011-06-21 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
WO2008117062A1 (en) 2007-03-28 2008-10-02 Aker Biomarine Asa Bioeffective krill oil compositions
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
DK2299998T3 (en) * 2007-11-02 2018-03-26 Prometic Pharma Smt Ltd MEDIUM-CHAINED FAT ACIDS AND GLYCERIDES AS NEPHROB PROTECTIVES
WO2010028336A2 (en) * 2008-09-08 2010-03-11 President And Fellows Of Harvard College Fatty acid c16:1n7-palmitoleate a lipokine and biomarker for metabolic status
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
EP2272383A1 (en) * 2009-06-22 2011-01-12 SBAE Industries NV Composition Comprising Omega-7 and/or Omega-4 Fatty Acids
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
WO2015064710A1 (ja) 2013-10-31 2015-05-07 久光製薬株式会社 アジュバント組成物、これを含むアジュバント製剤、及びキット
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
KR102152850B1 (ko) * 2014-03-28 2020-09-07 주식회사 엘지생활건강 글리세린 지방산 유도체의 용도
NZ747847A (en) 2015-02-11 2023-06-30 Aker Biomarine Antarctic As Lipid compositions
PL3256003T3 (pl) 2015-02-11 2023-05-22 Aker Biomarine Antarctic As Sposoby ekstrakcji lipidów
CA2977237A1 (en) * 2015-02-18 2016-08-25 Tersus Life Sciences, LLC Methods for improving joint function
EP3468551A4 (en) * 2016-06-08 2020-01-22 Sunregen Healthcare AG LIPIDS WITH ODD NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR A FOOD SUPPLEMENT
KR101817552B1 (ko) * 2016-10-13 2018-01-11 주식회사 엔지켐생명과학 모노아세틸디아실글리세롤 화합물을 함유하는 간염의 예방 또는 치료용 조성물
CN108853066A (zh) * 2018-09-20 2018-11-23 成都中医药大学 链式脂肪醇在制备抗炎、镇痛药物中的用途
CN112168812B (zh) * 2019-07-02 2022-07-08 瑞微（深圳）生物科技有限公司 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途
CN114544783B (zh) * 2020-11-20 2024-01-30 上海交通大学医学院附属瑞金医院 一种预防银屑病复发的内源性代谢物组合

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US612700A (en) * 1898-10-18 Disk plow
US6458772B1 (en) * 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4826818A (en) * 1983-10-26 1989-05-02 Kanebo Ltd. Proteinaceous emulsifier, process for preparing same and emulsion type cosmetic compositions containing same
CH679119A5 (hu) * 1988-05-13 1991-12-31 Sandoz Ag
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5194451A (en) * 1989-11-02 1993-03-16 Katz David H Systemic anti-inflammatory treatment
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
TW355153B (en) * 1996-05-21 1999-04-01 Toshiba Machine Co Ltd A method for leveling abrasive cloth and device for the same
DK1001759T3 (da) * 1996-09-17 2005-10-10 Avanir Pharmaceuticals Virusinhibering med langkædede alkoholer, alkaner, fedtsyrer og amider
AU731692C (en) * 1996-10-11 2001-10-11 Scarista Limited Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6210700B1 (en) * 1997-01-14 2001-04-03 Novartis Nutrition Ag Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
US6242426B1 (en) * 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
EP0919230A1 (en) * 1997-12-01 1999-06-02 Societe Des Produits Nestle S.A. NMIFA's as anti-inflammatory agents in superficial mammal tissues
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
BR9917389B1 (pt) * 1999-06-25 2013-04-24 formulaÇÕes tàpicas compreendendo agentes de penetraÇço na pele e o uso das mesmas.
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
BR0314554A (pt) * 2002-10-10 2005-08-09 Yeda Res & Dev ésteres básicos de álcoois graxos e sua aplicação como agentes anti-inflamatórios ou imunomoduladores

Also Published As

Publication number Publication date
NO20034558L (no) 2003-12-10
AU2002255241B2 (en) 2007-08-02
HUP0303881A2 (hu) 2004-03-01
PL366586A1 (en) 2005-02-07
CN1514723A (zh) 2004-07-21
EP1385500B1 (en) 2010-07-28
KR20030096312A (ko) 2003-12-24
IL142535A0 (en) 2002-03-10
NZ528784A (en) 2007-06-29
ATE475416T1 (de) 2010-08-15
EP1385500A4 (en) 2004-12-29
DE60237148D1 (de) 2010-09-09
WO2002083122A1 (en) 2002-10-24
ZA200307783B (en) 2004-10-06
EP1385500A1 (en) 2004-02-04
CN100352433C (zh) 2007-12-05
CA2442953A1 (en) 2002-10-24
JP2004525180A (ja) 2004-08-19
NO20034558D0 (no) 2003-10-10
MXPA03009341A (es) 2004-02-12
US20060183797A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
HUP0303881A3 (en) Pharmaceutical compositions containing fatty alcohols and fatty acid esters useful for treatment of inflammation
AU2001259159A1 (en) Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters
WO2003013497A1 (fr) Compositions s'averant efficaces pour prevenir ou soulager des troubles ou maladies provoques par une hypofonction cerebrale
HUP0101653A3 (en) Fatty acid derivatives of bile acids and bile acid derivatives and pharmaceutical compositions thereof
HUP0302781A3 (en) Ester derivatives of 4-iodo phenylamino benzhydroxamic acids and pharmaceutical compositions containing them
IS6205A (is) Lyfja- og næringarsamsetningar sem innihalda nauðsynlegar fitusýrur og hómósystein-lækkandi miðla
EE200300297A (et) Eikosapentaeenhappe etüülestri ja dokosaheksaeenhappe etüülestri segu sisaldava essentsiaalse rasvhappe kasutamine
HUP0400010A2 (hu) Eljárás zsírsavak terápiás hatásainak a javítására
ATE285783T1 (de) Feste lipidformulierung enthaltend lipasehemmer und fettsäureester von polyolen
EP1685218A4 (en) Fatty acid esters and their use
AU5377400A (en) Concentration and purification of polyunsaturated fatty acid esters by distillation-enzymatic transesterification coupling
AU3591301A (en) Ester derivatives of dimethylpropionic acid and pharmacetuical compositions containing them
HUP0304045A3 (en) Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them
ZA200502613B (en) Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
IL162937A0 (en) Pravastatin pharmaceutical formulations and methods of their use
SI1399152T1 (sl) Farmacevtski sestavek, ki obsega inhibitor lipaze in monoester saharoze z maĺ äśobno kislino
HUP0303796A3 (en) Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers
HUP0401046A3 (en) Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan
HUP0203884A3 (en) Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics and pharmaceutical compositions containing them
TWI348385B (en) Cosmetic composition containing ester of pentaerythritol and benzoic acid
EP1416795A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES OF MITOCHONDRIA
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0202457A3 (en) Substituted cinnamic acid derivatives as fatty acid synthase inhibitors and pharmaceutical compositions containing them
AU4666800A (en) Fatty acid esters of aromatic alcohols and their use in cosmetic formulations
AU2001259158A1 (en) Treatment of skin damage using acetyl carnitine and phosphatidylcholine and/or ascorbyl fatty acid esters

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees